{"id":180,"date":"2019-09-17T17:08:38","date_gmt":"2019-09-17T17:08:38","guid":{"rendered":"https:\/\/alivamab.com\/dev\/?p=180"},"modified":"2020-08-07T11:12:04","modified_gmt":"2020-08-07T18:12:04","slug":"alivamab-discovery-services-announces-multi-target-agreement-with-janssen","status":"publish","type":"post","link":"https:\/\/alivamab.com\/dev\/alivamab-discovery-services-announces-multi-target-agreement-with-janssen\/","title":{"rendered":"AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen"},"content":{"rendered":"<p style=\"text-align: center;\"><em>ADS to provide expertise and capabilities in antibody drug discovery<\/em><\/p>\n<p><strong>\u00a0<\/strong>SAN DIEGO, Calif. \u2013\u00a0 September 16, 2019 \u2013 <a href=\"https:\/\/alivamab.com\/dev\/\">AlivaMab Discovery Services, LLC,<\/a>\u00a0 a company providing custom human therapeutic antibody drug discovery services using the AlivaMab\u2122 Mouse, a best-in-class antibody discovery platform, today announced a multi-target discovery agreement with Janssen Research &amp; Development, LLC (Janssen).\u00a0 Under the agreement, ADS will provide its expertise and capabilities to generate and deliver therapeutic antibody candidates to Janssen for further evaluation.<\/p>\n<p>\"We are pleased that Janssen, a global leader in biologic drug discovery and development, has entrusted ADS as a partner in its therapeutic antibody discovery efforts,\u201d said \u201cLippy\u201d Lippincott, PhD, Vice-President of Research.\u00a0 \u201cADS is delivering potent, picomolar-affinity human antibodies to its partners, in a greater number and a shorter timeline that beats other transgenic animal and <em>in vitro<\/em> display platforms.\u00a0 Our team of experts looks forward to collaborating with colleagues at Janssen in using AlivaMab Mouse to discover therapeutic antibody candidates.\"<\/p>\n<h4><strong>About AlivaMab Discovery Services<\/strong><\/h4>\n<p>AlivaMab Discovery Services was founded by a team with proven success in the development and use of transgenic animals in the discovery of human therapeutic antibodies.\u00a0 The ADS team applies its decades of combined experience in therapeutic antibody discovery and development to each partner project to provide human therapeutic antibody discovery services customized for target type, antibody design goals, and needs of the partner.\u00a0 We offer a comprehensive suite of partner solutions from consulting on target product profile through delivery of antibody leads that meet or exceed our partner\u2019s project goals.\u00a0 For more information, please visit <a href=\"https:\/\/alivamab.com\/dev\">www.alivamab.com<\/a> or contact us at info@alivamab.com.<\/p>\n<h4>Media Contact:<\/h4>\n<p>Christine Quern<br \/>\n<a href=\"mailto:cq@christinequern.com\">cq@christinequern.com<\/a><br \/>\n617-650-8497<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADS to provide expertise and capabilities in antibody drug discovery \u00a0SAN DIEGO, Calif. \u2013\u00a0 September 16, 2019 \u2013 AlivaMab Discovery Services, LLC,\u00a0 a company providing custom human therapeutic antibody drug discovery services using the AlivaMab\u2122 Mouse, a best-in-class antibody discovery platform, today announced a multi-target discovery agreement with Janssen Research &amp; Development, LLC (Janssen).\u00a0 Under [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":435,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[],"_links":{"self":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/180"}],"collection":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/comments?post=180"}],"version-history":[{"count":2,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/180\/revisions"}],"predecessor-version":[{"id":403,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/posts\/180\/revisions\/403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/media\/435"}],"wp:attachment":[{"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/media?parent=180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/categories?post=180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alivamab.com\/dev\/wp-json\/wp\/v2\/tags?post=180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}